Daneshmand S et al. First results from SunRISE-1 in patients with BCG unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone. AUA 2023;Abstract LBA02-03.

Daneshmand S et al. Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non-muscle-invasive badder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis. Genitourinary Cancers Symposium 2023;Abstract 504.

Daneshmand S et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: A phase I trial. Urol Oncol 2022;40:344.e1-9. Abstract

Galsky MD et al. Extended follow-up results from the CheckMate 274 trial. Genitourinary Cancers Symposium 2023;Abstract LBA443.

Grivas P et al. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. Genitourinary Cancers Symposium 2022;Abstract 434.

Hoimes CJ et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol 2023:41(1):22-31. Abstract

Necchi A et al. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guérin: Results from Cohort B of the phase 2 KEYNOTE-057 trial. Genitourinary Cancers Symposium 2023;Abstract LBA442.

Petrylak DP et al. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy. Genitourinary Cancers Symposium 2022;Abstract 435.

Rosenberg JE et al. Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma. ASCO 2022;Abstract 4516.

Rosenberg JE et al. Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). ESMO 2022;Abstract LBA73.

Sheng X et al. RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. ASCO 2022;Abstract 4520.

Siefker-Radtke A et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. Lancet Oncol 2022;23(2):248-58. Abstract

Tagawa ST et al. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Genitourinary Cancers Symposium 2023;Abstract 526.

van Valenberg FJP et al. Safety, tolerability, and preliminary efficacy of TAR-200 in intermediate-risk non-muscle-invasive bladder cancer patients: A phase 1 study. Genitourinary Cancers Symposium 2023;Abstract 505.

Williams SB et al. A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder. ASCO 2021;Abstract TPS4586.

Xu H et al. A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. ASCO 2022;Abstract 4519.